The Opioid Use Disorder Market consists of drugs used for the treatment of opioid use disorder. Opioid use disorder occurs when a person develops a problematic pattern of using opioids that causes significant impairment or distress. Opioids are a class of drugs that include pain relievers like oxycodone, hydrocodone, codeine, morphine, and others. Opioids work by binding to opioid receptors in the brain and body to reduce the intensity of pain signals reaching the brain. However, their use can lead to severe addiction. Currently approved drugs for opioid use disorder include buprenorphine and methadone which are known as opioid agonist treatment medications. These act on the same receptors as opioids but have a ceiling effect.
The Global Opioid Use Disorder Market is estimated to be valued at US$ 3728.51 Bn in 2024 and is expected to exhibit a CAGR of 8.0% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Opioid Use Disorder market are Moog Inc., Honeywell International Inc., AMETEK Inc., TE Connectivity, Woodward Inc., General Dynamics Corporation, Parker Hannifin Corp, Sensata Technologies, Tamagawa Seiki Co., Ltd., LTN Servotechnik GmbH, Maxon Group, Bevone, Danaher Corporation, Kollmorgen, TE Connectivity, ALXION, Micronor, Elmo Motion Control, Electro-Sensors, and Siko GmbH. These players are focusing on developing novel treatment options with improved efficacy and safety profiles.
The demand for opioid use disorder treatment is growing significantly owing to the rising prevalence of addiction. According to the National Survey on Drug Use and Health, around 2 million people had opioid use disorder in 2019 in the United States alone.
The market is also witnessing expansion in developed as well as developing regions owing to increasing awareness about evidence-based treatment options and supportive government policies for opioid use disorder management. Companies are focusing on late-phase clinical trials as well as geographic expansion to tap growth opportunities.
Market Key Trends
One of the key trends gaining traction in the Opioid Use Disorder Market Demand is the development of non-opioid based innovative treatment options. Considering the risks associated with long term use of opioid agonist drugs, there is a rising focus on developing non-addictive alternatives. Players are conducting research on new therapeutic targets such as opioid growth factor, cannabidiol, anti-craving medications, and opioid receptor antagonists. Some pipeline candidates have demonstrated promising results for relapse prevention in clinical trials. This innovation-led approach is expected to transform the opioid use disorder treatment landscape in the long run.
Porter’s Analysis
Threat of new entrants: The threat of new entrants to the opioid use disorder market is low as it requires substantial investment in R&D and clinical trials to develop new drug therapies. The market is dominated by major pharmaceutical companies with established distribution networks.
Bargaining power of buyers: The bargaining power of buyers in the opioid use disorder market is moderate. Pharmaceutical buyers include hospitals, pharmacies, and healthcare providers. They can leverage their purchasing power to negotiate lower drug prices from suppliers.
Bargaining power of suppliers: The bargaining power of suppliers is moderate. Major global pharmaceutical suppliers control the licensing and production of opioid addiction drugs. Suppliers strategically collaborate with buyers to ensure stable supply of niche therapies at negotiated prices.
Threat of new substitutes: The threat of new substitutes is low as developing new non-opioid based drug therapies for addiction treatment requires significant investments and time for clinical validation. Existing pharmacotherapies have well-established efficacy benefits over alternative treatment options.
Competitive rivalry: The competitive rivalry in the market is high due to the dominance of a few large players. Manufacturers compete based on new drug innovations, portfolio expansion into adjunct therapies, and strategic partnerships. Manufacturing generics further intensifies competition.
Geographical Regions
North America dominates the opioid use disorder market with the largest value share. The region has a high prevalence of prescription opioid abuse and misuse disorders. Favorable regulatory environment and reimbursement policies have supported the adoption of pharmacotherapies.
Asia Pacific is the fastest growing region for the opioid use disorder market owing to improving access to healthcare, rising awareness about addiction treatment, and economic expansion. China, India, Japan, and South Korea are major contributors to the regional market growth.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
